HER2+ Breast Cancer

Kelly McCann, MD, PhD, discusses the therapies available for patients with HER2-positive breast cancer and the potential benefit with additional subtyping in the field.

A panel of experts discuss the latest developments in the treatment of patients with HER2-positive breast cancer.

Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the promise of immunotherapy in the treatment of patients with HER2-positive breast cancer.

There are multiple therapeutic options in development for the treatment of patients with HER2-positive breast cancer, further adding to the regimens available, explains Frances Valdes-Albini, MD.

Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the FDA approval of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses emerging agents for the treatment of HER2-positive breast cancer.

Mark D. Pegram, MD, discusses the evolving treatment paradigm of HER2-positive breast cancer.

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the benefit of pertuzumab (Perjeta) plus trastuzumab (Herceptin) for patients with HER2-positive breast cancer.

Jean-Bernard Durand, MD, professor in the Department of Cardiology at The University of Texas MD Anderson Cancer Center, discusses advice for community oncologists on managing patients that are experiencing symptoms from treatment for HER2-positive breast cancer.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses developing agents for patients with HER2-positive breast cancer who have brain metastases.

William J. Gradishar, MD, interim chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the treatment of HER2-positive breast cancer.

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses advancements in adjuvant HER2-positive breast cancer.

Sara Hurvitz, MD, and Sunil Verma, MD, share their expert insight on the latest groundbreaking developments in HER2-positive breast cancer.

Jean-Bernard Durand, MD, associate professor in the Department of Cardiology at The University of Texas MD Anderson Cancer Center, discusses protecting patients’ hearts from anthracyclines and HER2-targeted therapies when treating for HER2-positive breast cancer.

Jean-Bernard Durand, MD, discusses the possibility of repairing cardiac damage in patients with HER2-positive breast cancer.

Elizabeth A. Mittendorf, MD, PhD, associate professor in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center, discusses the impact of pertuzumab (Perjeta) on the treatment landscape of HER2-positive breast cancer.

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses novel agents that are emerging in the HER2-positive breast cancer space. Hurvitz shared this insight in an interview with OncLive during the 35th Annual Miami Breast Cancer Conference.

The discovery of crosstalk between the HER2 and hormone receptor pathways has led to the promising treatment strategy of dual targeting regimens.

Several new agents have emerged in HER2-positive breast cancer with the potential to further alter the natural course of the disease.

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the HER2CLIMB study in patients with HER2-positive breast cancer.

A blood test that detects early changes in circulating tumor DNA may provide an earlier indication of whether patients with hormone receptor–positive, HER2-negative breast cancer are responding to palbociclib (Ibrance).

European regulators have recommended against approving a marketing authorization application for the use of neratinib (Nerlynx) as extended adjuvant treatment for women with early stage HER2-positive breast cancer.

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses HER2 blockade in the treatment of patients with HER2-positive breast cancer.

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neratinib (Nerlynx) in HER2-positive breast cancer.